An Israeli startup is revolutionizing healthcare by developing lab-made universal red blood cells, eliminating the need for donors.

The research, which suggests the body's circadian clock influences its response to oxygen deficiency, could help maximize the effectiveness of treatment.

The patients were brought in a convoy of ambulances to Ramon Airport, situated near Eilat, where they embarked on flights to receive care abroad.

The studies — led by Professor Uri Ben-David and doctoral student Johanna Zerbib in Tel Aviv, and Professor Stefano Santaguida and doctoral student Marica Rosaria Ippolito in Milan — discovered two main weaknesses in aneupoloid cells.

What makes this treatment particularly remarkable is its effectiveness—early results indicate that over 80% of patients have experienced significant relief.

Further research is needed to determine if manipulating the gut microbiome could be a viable treatment approach for ASD.

The new treatment works on patients who already have the coronavirus and is being fast-tracked for patenting and production.